Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease
Authors:
- Steven L. WerlinSWSteven L. Werlin
- Daryl FishDFDaryl Fish
- Mathew ScanlonMSMathew Scanlon
- Patrick HanawayPHPatrick Hanaway
- Subra KugathasanSKSubra Kugathasan
- 1 May 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 14 (5) , 669-673
Abstract
Fecal calprotectin (FC) has been proposed as a noninvasive surrogate marker to determine the degree of intestinal inflammation and predicting relapse in patients with inflammatory bowel disease (IBD). The aim was to compare FC levels in IBD and healthy controls, to correlate FC levels with clinical disease activity, and to assess whether FC levels can be used to predict clinical relapse in children with IBD. Enzyme-linked immunosorbent assay (ELISA) determined levels of FC were measured in more than 1 stool samples (n) from 32 IBD patients (n = 97) and from 34 healthy controls (n = 37). Disease activity was assessed by the Harvey-Bradshaw index in Crohn's disease (CD) and by Physician's Global Assessment (PGA) in both CD and ulcerative colitis (UC). Clinical events were recorded up to 9 months following stool collection in CD patients. Wilcoxon rank sum test and Fisher's exact tests were used to compare FC levels in IBD patients and in control. Kaplan-Meyer analysis was used to determine a risk of clinical relapse in relation to FC levels. The IBD group had higher FC levels (range 17-7500 g/g) compared with control (16-750 g/g, P < 0.0001). FC levels were higher during relapse (CD, 3214 +/- 2186; UC, 2819 +/- 1610) compared to remission (CD, 1373 +/- 1630; UC, 764 +/- 869; P < 0.0001). Among those with clinical relapse, 90% had FC levels more than 400 mug/g in CD. Eighty-nine percent of CD encounters with FC levels less than 400 mug/g remained in clinical remission. FC levels differentiate active IBD from controls. Among children with CD and in remission, FC levels may be useful in predicting impending clinical relapse.Keywords
This publication has 35 references indexed in Scilit:
- Determination of faecal calprotectin, a novel marker of organic gastrointestinal disordersDigestive and Liver Disease, 2003
- Calprotectin (S100A8/S100A9), an Inflammatory Protein Complex from Neutrophils with a Broad Apoptosis-Inducing ActivityBiological and Pharmaceutical Bulletin, 2003
- Faecal calprotectin: a marker of inflammation throughout the intestinal tractEuropean Journal of Gastroenterology & Hepatology, 2002
- Calprotectin, a faecal marker of organic gastrointestinal abnormalityThe Lancet, 2000
- Relationship between Intestinal Permeability and Calprotectin Concentration in Gut Lavage FluidScandinavian Journal of Gastroenterology, 2000
- Correlation between Faecal Excretion of Indium-111-Labelled Granulocytes and Calprotectin, a Granulocyte Marker Protein, in Patients with Inflammatory Bowel DiseaseScandinavian Journal of Gastroenterology, 1999
- Functional and clinical aspects of the myelomonocyte protein calprotectin.Molecular Pathology, 1997
- Induction of apoptotic cell death in mouse lymphoma and human leukemia cell lines by a calcium-binding protein complex, calprotectin, derived from inflammatory peritoneal exudate cellsJournal of Leukocyte Biology, 1995
- Antimicrobial Activity of an Abundant Calcium-Binding Protein in the Cytoplasm of Human NeutrophilsThe Journal of Infectious Diseases, 1991
- Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectinThe Lancet, 1990